4CPS-116 Study of effectiveness and safety of cytoreductive surgery associated with HIPEC in patients with peritoneal carcinomatosis

<h3>Background and Importance</h3> Hyperthermic intraperitoneal chemotherapy (HIPEC) is a method of administering chemotherapy directly while heating the abdominal cavity. <h3>Aim and Objectives</h3> The aim of the study is to evaluate effectiveness and safety of cytoreductive surgery(CRS) associated with HIPEC(Hyperthermic Intraperitoneal Chemotherapy) in patients with peritoneal carcinomatosis in real-life in a tertiary hospital. <h3>Material and Methods</h3> Retrospective descriptive study (March 2018-September 2024) that included all patients with peritoneal carcinomatosis who received (CRS) associated with HIPEC in a tertiary hospital. We evaluated the efficacy of this technique in real-life data according to evidence from different studies in ovarian cancer, colorectal cancer and appendiceal psedomyxoma. Demographic, clinical variables such as PCI (peritoneal carcinomatosis index) and treatment-related variables were collected from the electronic medical record and outpatient programme. The main efficacy variables were: progression-free survival (PFS) and overall survival (OS). Safety was determined by postoperative complications. Data were analysed using SPSS <h3>Results</h3> Thirty-four patients were included, 24 women (70.5%), median age 63 years (45–76), 18 with colorectal tumour, 13 with ovarian tumour and 3 with appendiceal pseudomyxoma. The ECOG range was 0 to 2 (ECOG 0: n=14; ECOG 1: n=9; ECOG 2: n=2). The median number of PCIs was 11 (2–24). Fourteen patients had metastatic status, of which twelve were advanced, one adjuvant and one unknown. At the study cut-off date (30/09/2024), with a median follow-up of 22.7 months (0.5–76), the median number of prerelapse lines was 1 (0–2) and the median number of postrelapse lines was 1 (0–5). The drugs used were 5-FU + oxaliplatin in 12 patients, mitomycin in 9 and cisplatin in 13. Seventeen progressions and twelve deaths were observed. The median duration of surgery was 420 minutes (280–810), with a median hospital stay of 15 days (6–67). The median PFS was 7.6 months(95% CI 11–7–4.03) and OS 17.62 months(95% CI 22–1–13.1). Regarding complications: seven patients suffered abdominal wall complications, nine gastrointestinal, four respiratory; four infectious, eight others. <h3>Conclusion and Relevance</h3> Although our population appears to benefit from HIPEC, indirect comparisons were not feasible due to differences between populations. A longer follow-up and a larger sample size are recommended to compare each pathology separately. Most HIPEC-related complications are linked to the complexity of the surgical procedure. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest